A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...
Zacks Investment Research on MSN
INCY's phase III Monjuvi study meets key goals in first-line lymphoma
Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...
Incyte has reported positive top line data from the pivotal Phase III frontMIND trial assessing the safety and efficacy of ...
Incyte (INCY) on Monday posted a Phase 3 trial win for tafasitamab, an antibody therapy it has developed with Xencor (XNCR), ...
A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.
Incyte said on Monday its experimental combo therapy helped patients with a type of blood cancer live longer without their ...
Diffuse large B-cell lymphoma (DLBCL) account for approximately 40% of adult non-Hodgkin lymphomas. It is clinically, morphologically and genetically a heterogeneous group of tumors composed of large ...
Diffuse lymphomas of B-cell origin represent a heterogeneous group of lymphoid neoplasms. The histologically aggressive subtypes of diffuse B-cell lymphomas include biologically different entities, ...
US biotech Incyte (Nasdaq: INCY) yesterday announced positive top-line results from the pivotal Phase III frontMIND trial ...
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase We retrospectively analyzed 38 patients with ALK-positive DLBCL treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback